期刊
SCIENCE SIGNALING
卷 10, 期 462, 页码 -出版社
AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/scisignal.aal2328
关键词
-
资金
- U.S. NIH, National Cancer Institute, Center for Cancer Research
- University of Macau [SRG2014-00024-ICMS-QRCM, MYRG2016-00023-ICMS-QRCM]
- Science and Technology Development Fund [Macao S.A.R.] [014/2015/A1]
Tumor necrosis factor receptor type II (TNFR2) is expressed both by some cancer cells and by tumor-infiltrating immunosuppressive CD4(+)FoxP3(+) regulatory T cells (T-regs). TNFR2 stimulates the activation and proliferation of T-regs, a major checkpoint of antitumor immune responses, and promotes cancer cell survival and tumor growth. In this issue of Science Signaling, Torrey et al. found that dominant antagonistic antibodies against human TNFR2 may be a potential therapy for ovarian cancer patients by simultaneously suppressing T-reg activity and inducing the death of the cancer cells.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据